BRIEF—Phase III trial misses primary endpoint, Neovii reveals

Switzerland’s Neovii Pharmaceuticals has published Phase III data for Grafalon (anti-T lymphocyte globulin or ATLG) as a treatment for graft-versus-host-disease (cGVHD).

The trial did not meet its primary endpoint. The company says the trial did show: “A statistically significant reduction in acute GVHD II-IV as well as moderate and severe cGVHD.”

The head of Neovii North America said: “While Grafalon is approved and used for GVHD prophylaxis in many countries, US patients currently don't have an FDA approved treatment option to prevent cGVHD."